Drug delivery system and method of manufacturing thereof

ABSTRACT

In one embodiment, a drug delivery system and method provide a member including a combination of a drug substance and a polymer or other material, and an encapsulating layer formed in an outer surface of the member by gas cluster ion beam irradiation of the outer surface of the member, which encapsulating layer is adapted to determine one or more characteristics of the drug delivery system.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No.11/550,069 filed Oct. 17, 2006, entitled “Drug Delivery System andMethod of Manufacturing Thereof,” which in turn is acontinuation-in-part application of U.S. patent application Ser. No.11/349,483 entitled “Drug Delivery System and Method of ManufacturingThereof”, filed Feb. 7, 2006, which in turn is a continuation-in-part ofU.S. patent application Ser. No. 10/144,919 entitled “Method and Systemfor Improving the Effectiveness of Medical Devices by Adhering Drugs tothe Surface Thereof”, filed 13 May 2002, issued as U.S. Pat. No.7,105,199, which claims the benefit of priority of U.S. provisionalapplication Ser. Nos. 60/290,389 filed May 11, 2001, and 60/317,652filed Sep. 6, 2001, each entitled “Method and System for Improving theEffectiveness of Medical Devices by Applying/Adhering Drugs to theirSurface in Combination with the Application of Ion Beam Technology”, andeach being incorporated herein by reference in their entirety for allpurposes.

FIELD OF THE INVENTION

This invention relates generally to drug delivery systems such as, forexample, medical devices implantable in a mammal (e.g., coronary stents,prostheses, etc.), and more specifically to a system and method forcontrolling the surface characteristics of such drug delivery systemssuch as, for example, the drug release rate and bio-reactivity.

BACKGROUND OF THE INVENTION

A coronary stent is an implantable medical device that is used incombination with balloon angioplasty. Balloon angioplasty is a procedureused to treat coronary atherosclerosis. Balloon angioplasty compressesbuilt-up plaque against the walls of the blocked artery by the inflationof a balloon at the tip of a catheter inserted into the artery duringthe angioplasty procedure. Unfortunately, the body's response to thisprocedure often includes thrombosis or blood clotting and the formationof scar tissue or other trauma-induced tissue reactions at the treatmentsite. Statistics show that restenosis or re-narrowing of the artery byscar tissue after balloon angioplasty occurs in up to 35 percent of thetreated patients within only six months after these procedures, leadingto severe complications in many patients.

To reduce restenosis, cardiologists are now often placing small tubulardevices of various forms, such as wire mesh; expandable metal; andnon-degradable and biodegradable polymers called a coronary stent at thesite of blockage during balloon angioplasty. The goal is to have thestent act as a scaffold to keep the coronary artery open after theremoval of the balloon.

However, there are also serious complications associated with the use ofcoronary stents. Coronary restenotic complications associated withstents occur in 16 to 22 percent of all cases within six months afterinsertion of the stent and are believed to be caused by many factorsacting alone or in combination. These complications could be reduced byseveral types of drugs introduced locally at the site of stentimplantation. Because of the substantial financial costs associated withtreating the complications of restenosis, such as catheterization,restenting, intensive care, etc., a reduction in restenosis rates wouldsave money and reduce patient suffering.

Numerous studies suggest that the current popular designs of coronarystents are functionally equivalent. Although the use of coronary stentsis growing, the benefits of their use remain controversial in certainclinical situations or indications due to their potential complications.It is widely held that during the process of expanding the stent, damageoccurs to the endothelial lining of the blood vessel triggering ahealing response that re-occludes the artery. To help combat thatphenomenon, drug-coated stents are being introduced to the market tohelp control the abnormal cell growth associated with this healingresponse. These drugs are typically mixed with a liquid polymer andapplied to the stent surface, The polymer coating can include severallayers such as the above drug containing layer as well as a drug freeencapsulating layer, which can help to reduce the initial drug releaseamount caused by initial exposure to liquids when the device is firstimplanted. A further base coating of polymer located beneath the drugbearing layer is also known. One example of this arrangement used onstainless steel stents includes a base layer of Paralene C. and adrug/polymer mixture including polyethylene-co-vinyl acetate (PEVA) andpoly n-butyl methacrylate (PBMA) in a two to one ratio, along with annon-drug impregnated top layer of the same mixture of PEVA and PBMA. Thedrug used is Sirolirnus, a relatively new immunosuppressant drug alsoknown as Rapamycin. Several other drug/polymer combinations exist fromseveral manufactures.

In view of this new approach to in situ drug delivery, it is desirableto have greater control over the drug release rate from the implantabledevice as well as control over other surface characteristics of the drugdelivery medium.

It is therefore an object of this invention to provide a means ofcontrolling surface characteristics of a drug eluting material using gascluster ion beam technology.

It is a further object of this invention to improve the functionalcharacteristics of known in situ drug release mechanisms using gascluster ion beam technology.

SUMMARY OF THE INVENTION

The objects set forth above as well as further and other objects andadvantages of the present invention are achieved by the inventiondescribed herein below.

In one embodiment, a drug delivery system, comprises a member includinga combination of a drug substance and a polymer or other material, andan encapsulating layer formed in an outer surface of the member by gascluster ion beam irradiation of the outer surface of the member, whichencapsulating layer is adapted to determine a release rate for the drugfrom the member.

The encapsulating layer may include a plurality of openings located atan outer surface of the encapsulating layer and adapted to permitamounts of the drug substance to be released from the member at a ratedetermined by the encapsulating layer. The encapsulating layer mayinclude a carbonized or densified matrix. The encapsulating layer may beadapted to improve a measure of biocompatibility of the member.

The member may be located on a surface of a medical device. The drugsubstance may be selected from the group consisting of anti-coagulants,antibiotics, anti-tumor substances, immune-suppressing agents,vasodilators, anti-prolifics, anti-thrombotic substances, anti-plateletsubstances, cholesterol reducing agents and combinations thereof.

A medical device may include the drug delivery system described above.

In another embodiment, a drug delivery system comprises a cohesivemixture including a combination of a drug substance and a polymer orother material, and a carbonized or densified matrix formed on an outersurface of the cohesive mixture, which carbonized or densified matrix isadapted to determine a release rate for the drug substance from thecohesive mixture.

In yet another embodiment, a method for producing a drug deliverysystem, comprises the steps of providing a member including acombination of a drug substance and a polymer or other material, andirradiating an outer surface of the member with a gas cluster ion beamto determine a release rate for the drug substance from the member.

The step of providing a member may include forming a cohesive mixture ofthe drug substance and the polymer or other material on a surface of amedical device. The step of irradiating may include forming anencapsulating layer on at least an external surface of the member, whichencapsulating layer is adapted to control release of the drug substancefrom the member. The encapsulating layer may include a plurality ofopenings at an outer surface of the encapsulating layer so as to permitportions of the drug substance to be released from the member at a ratedetermined by the encapsulating layer. The encapsulating layer mayinclude a carbonized or densified matrix.

The step of providing a member may include the steps of providing apolymer element and adhering a drug substance to an outer surface of thepolymer element. The step of providing a polymer element may include thestep of irradiating the outer surface of the polymer element with a gascluster ion beam prior to the step of adhering. The step of irradiatingmay be adapted to lower in situ chemical reactivity of the externalsurface of the cohesive mixture. The drug substance may be selected fromthe group consisting of anti-coagulants, antibiotics, anti-tumorsubstances, immune-suppressing agents, vasodilators, anti-prolifics,anti-thrombotic substances, anti-platelet substances, cholesterolreducing agents and combinations thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

For a better understanding of the present invention, together with otherand further objects thereof, reference is made to the accompanyingdrawings, wherein:

FIG. 1 is a schematic view of a gas cluster ion beam processing systemused for practicing the method of the present invention;

FIG. 2 is an exploded view of a portion of the gas cluster ion beamprocessing system of FIG. 1 showing the workpiece holder;

FIG. 3 is an atomic force microscope image showing the surface of acoronary stent before GCIB processing;

FIG. 4 is an atomic force microscope image showing the surface of acoronary stent after GCIB processing;

FIG. 5 is across section of a drug delivery system prior to processingin accordance with the present invention;

FIG. 6 is a cross section of the drug delivery system of FIG. 5 shownduring gas cluster ion beam processing performed in accordance with thepresent invention;

DETAILED DESCRIPTION OF THE DRAWINGS

Beams of energetic ions, electrically charged atoms or moleculesaccelerated through high voltages under vacuum, are widely utilized toform semiconductor device junctions, to smooth surfaces by sputtering,and to enhance the properties of semiconductor thin films. hi thepresent invention, these same beams of energetic ions are utilized foraffecting surface characteristics of drug eluting medical devices, suchas, for example, coronary stents, thereby enhancing the drug deliveryproperties and the bio-compatibility of such drug delivery systems.

In the preferred embodiment of the present invention, gas cluster ionbeam GCIB processing is utilized. Gas cluster ions are formed from largenumbers of weakly bound atoms or molecules sharing common electricalcharges and accelerated together through high voltages to have hightotal energies. Cluster ions disintegrate upon impact and the totalenergy of the cluster is shared among the constituent atoms. Because ofthis energy sharing, the atoms are individually much less energetic thanthe case of conventional ions or ions not clustered together and, as aresult, the atoms penetrate to much shorter depths. Surface sputteringeffects are orders of magnitude stronger than corresponding effectsproduced by conventional ions, thereby making important microscalesurface effects possible that are not possible in any other way.

The concept of GCIB processing has only emerged over the past decade.Using a GCIB for dry etching, cleaning, and smoothing of materials isknown in the art and has been described, for example, by Deguchi, et al,in U.S. Pat. No. 5,814,194, “Substrate Surface Treatment Method”, 1998.Because ionized clusters containing on the order of thousands of gasatoms or molecules may be formed and accelerated to modest energies onthe order of a few thousands of electron volts, individual atoms ormolecules in the clusters may each only have an average energy on theorder of a few electron volts. It is known from the teachings of Yamadain, for example, U.S. Pat. No. 5,459,326, that such individual atoms arenot energetic enough to significantly penetrate a surface to cause theresidual sub-surface damage typically associated with plasma polishing.Nevertheless, the clusters themselves are sufficiently energetic (somethousands of electron volts) to effectively etch, smooth, or clean hardsurfaces.

Because the energies of individual atoms within a gas cluster ion arevery small, typically a few eV, the atoms penetrate through only a fewatomic layers, at most, of a target surface during impact. This shallowpenetration of the impacting atoms means all of the energy carried bythe entire cluster ion is consequently dissipated in an extremely smallvolume in the top surface layer during a period on the order of 10⁻¹²seconds (i.e. one picosecond). This is different from the case of ionimplantation which is normally done with conventional monomer ions andwhere the intent is to penetrate into the material, sometimespenetrating several thousand angstroms, to produce changes in thesurface properties of the material. Because of the high total energy ofthe cluster ion and extremely small interaction volume, the depositedenergy density at the impact site is far greater than in the case ofbombardment by conventional monomer ions.

Reference is now made to FIG. 1 of the drawings which shows the GCIBprocessor 100 of this invention utilized for applying or adhering drugsto the surface of a medical device such as, for example, coronary stent10. Although not limited to the specific components described herein,the processor 100 is made up of a vacuum vessel 102 which is dividedinto three communicating chambers, a source chamber 104, anionization/acceleration chamber 106, and a processing chamber 108 whichincludes therein a uniquely designed workpiece holder 150 capable ofpositioning the medical device for uniform GCIB bombardment and drugapplication by a gas cluster ion beam.

During the processing method of this invention, the three chambers areevacuated to suitable operating pressures by vacuum pumping systems 146a, 146 b, and 146 c, respectively. A condensable source gas 112 (forexample argon or N₂) stored in a cylinder 111 is admitted under pressurethrough gas metering valve 113 and gas feed tube 114 into stagnationchamber 116 and is ejected into the substantially lower pressure vacuumthrough a properly shaped nozzle 110, resulting in a supersonic gas jet118. Cooling, which results from the expansion in the jet, causes aportion of the gas jet 118 to condense into clusters, each consisting offrom several to several thousand weakly bound atoms or molecules. A gasskimmer aperture 120 partially separates the gas molecules that have notcondensed into a cluster jet from the cluster jet so as to minimizepressure in the downstream regions where such higher pressures would bedetrimental (e.g., ionizer 122, high voltage electrodes 126, and processchamber 108). Suitable condensable source gases 112 include, but are notnecessarily limited to argon, nitrogen, carbon dioxide, oxygen.

After the supersonic gas jet 118 containing gas clusters has beenformed, the clusters are ionized in an ionizer 122, The ionizer 122 istypically an electron impact ionizer that produces thermo-electrons fromone or more incandescent filaments 124 and accelerates and directs theelectrons causing them to collide with the gas clusters in the gas jet118, where the jet passes through the ionizer 122. The electron impactejects electrons from the clusters, causing a portion the clusters tobecome positively ionized. A set of suitably biased high voltageelectrodes 126 extracts the cluster ions from the ionizer 122, forming abeam, then accelerates the cluster ions to a desired energy (typicallyfrom 1 keV to several tens of keV) and focuses them to form a GCIB 128having an initial trajectory 154. Filament power supply 136 providesvoltage V_(F) to heat the ionizer filament 124. Anode power supply 134provides voltage V_(A) to accelerate thermoelectrons emitted fromfilament 124 to cause them to bombard the cluster containing gas jet 118to produce ions. Extraction power supply 138 provides voltage V_(E) tobias a high voltage electrode to extract ions from the ionizing regionof ionizer 122 and to form a GCS 128. Accelerator power supply 140provides voltage V_(Acc) to bias a high voltage electrode with respectto the ionizer 122 so as to result in a total GCIB acceleration energyequal to V_(Acc), electron volts (eV). One or more lens power supplies(142 and 144, for example) may be provided to bias high voltageelectrodes with potentials (V_(L1) and V_(L2) for example) to focus theGCIB 128.

A medical device, such as coronary stent 10, to be processed by the GCIBprocessor 100 is held on a workpiece holder 150, and disposed in thepath of the GCIB 128 for irradiation. The present invention may beutilized with medical devices composed of a variety of materials, suchas metal, ceramic, polymer, or combinations thereof. In order for thestent to be uniformly processed using GCM, the workpiece holder 150 isdesigned in a manner set forth below to manipulate the stent 10 in aspecific way.

Referring now to FIG. 2 of the drawings, medical device surfaces thatare non-planar, such as those of stents, must remain oriented within aspecific angle tolerance with respect to the normal beam incidence toobtain paramount effect to the stent surfaces utilizing GCIB. Thisrequires a fixture or workpiece holder 150 with the ability to be fullyarticulated to orient all non-planar surfaces of stent 10 to be modifiedwithin that specific angle tolerance at a constant exposure level forprocess optimization and uniformity. Any stent 10 containing surfacesthat would be exposed to the process beam at angles of greater than+/−15 degrees from normal incidence may require manipulation. Morespecifically, when applying GCIB to a coronary stent 10, the workpieceholder 150 is rotated and articulated by a mechanism 152 located at theend of the GCIB processor 100. The articulation/rotation mechanism 152preferably permits 360 degrees of device rotation about longitudinalaxis 154 and sufficient device articulation about an axis 156perpendicular to axis 154 to maintain the stent's surface to within+/−15 degrees from normal beam incidence.

Referring back to FIG. 1, under certain conditions, depending upon thesize of the coronary stent 10, a scanning system may be desirable toproduce uniform smoothness. Although not necessary for GCIB processing,two pairs of orthogonally oriented electrostatic scan plates 130 and 132may be utilized to produce a raster or other scanning pattern over anextended processing area. When such beam scanning is performed, a scangenerator 156 provides X-axis and Y-axis scanning signal voltages to thepairs of scan plates 130 and 132 through lead pairs 158 and 160respectively. The scanning signal voltages are commonly triangular wavesof different frequencies that cause the GCIB 128 to be converted into ascanned GCIB 148, which scans the entire surface of the stent 10.Additional means for orienting, articulating and/or rotating devicessuch as stents and orthopedic products are disclosed in U.S. Pat. No.6,491,800 to Kirkpatrick, et al., U.S. Pat. No. 6,676,989 toKirkpatrick, et al., and U.S. Pat. No. 6,863,786 to Blinn, et al., thecontents of each which are hereby incorporated by reference.

When beam scanning over an extended region is not desired, processing isgenerally confined to a region that is defined by the diameter of thebeam. The diameter of the beam at the stent's surface can be set byselecting the voltages (V_(L1) and/or V_(L2)) of one or more lens powersupplies (142 and 144 shown for example) to provide the desired beamdiameter at the workpiece.

In one processing step related to the present invention, the surface ofa medical device is irradiated with a GCIB prior to the deposition ofany substance on the surface thereof. This will remove any contaminantsand oxide layers from the stent surface rendering the surfaceelectrically active and capable of attracting and bonding drug andpolymer molecules that are then introduced to the surface.

As the atomic force microscope (AFM) images shown in FIGS. 3 and 4demonstrate, it is possible to dramatically affect the medical devicesurface utilizing gas cluster ion beam processing. FIG. 3 shows a stentsurface before GCIB treatment with gross surface micro-roughness on astrut edge. The surface roughness measured an R_(a) of 113 angstroms andan R_(RMS) of 148 angstroms. These irregularities highlight the surfacecondition at the cellular level where thrombosis begins. FIG. 4 showsthe stent surface after GCIB processing where the surfacemicro-roughness has been eliminated without any measurable physical orstructural change to the integrity of the stent itself. The post-GCIBsurface roughness measured an R_(a) of 19 angstroms and an R_(RMS) of 25angstroms. In this manner, GCIB processing also provides the addedbenefit of smoothing the surface of the medical device. Non-smoothsurfaces may snare fibrinogen, platelets, and other matter furtherpromoting stenosis.

With reference to FIG. 5, a drug delivery system 10, which includes adrug containing medium 12 and an optional substrate or medical device14, is shown prior to processing by the method of the present invention.Medical device 14 is only representational and may take any suitableform. Device 14 may include an implantable medical device such as astent or any other medical device which may benefit from an in situ drugdelivery mechanism. Optionally, the use of substrate or device 14 may belimited to the fabrication of drug containing medium 12, whereinsubstrate or device 14 is removed from medium 12 prior to implantation.Substrate or device 14 maybe he constructed of any suitable materialsuch as, for example, metal, ceramic or a polymer. Portions of substrateor device 14 may also be surface treated using GCIB in accordance withthe method mentioned above, prior to the application of drug/polymermedium 12.

Drug containing medium 12 may take any suitable form such as the variouspolymer arrangements discussed above. Medium 12 may include just asingle layer of drug containing material, or it may include multiplelayers 16, 18, 20, as described above. Although the existing artidentifies the use of an outer layer to control initial drug release,the process of the present invention may be used with this knownarrangement to further control surface characteristics of the medium,including the drug release rate after initial in situ liquid exposure.Drug medium 12 may be applied to device 14 in any suitable arrangementfrom just a portion to complete or almost complete enclosure of device14.

One method of application of medium 12 to device 14 uses a drug polymermixture with a volatile solvent, which is deposited upon a surface ofdevice 14. The solvent is evaporated to leave a cohesive drug/polymermixture in the form of medium 12, attached to the substrate. Once thesolvent is evaporated, drug medium 12 may form a cohesive mixture ormass and thereby provide a suitable drug delivery system, even in theabsence of device 14.

With reference to FIG. 6, the drug delivery system 10 is shownundergoing irradiation with a gas cluster ion beam. A stream 30 of gascluster molecules is being scanned across the cross section of drugdelivery device 10. The clusters 32 break up upon impact with thesurface 34 resulting in the shallow implantation of individual or smallgroups of molecules 36. Most of the individual molecules 36 stop withinthe first couple of molecular levels of medium 12 with the result thatmost of a thin layer 38 at surface 34 is densified or carbonized by theimpinging molecules. The sealing of surface 34 is not complete, asvarious openings 39 remain in surface 34 which openings allow for theelution of drugs from medium 12. Thus, it is through the amount of GCIBirradiation that the characteristics of surface 34 are determined. Thegreater the amount of irradiation, the fewer and smaller are theopenings in surface 34, thereby slowing the release of drugs from medium12. Also, this densification or carbonization of surface 34 causespacification or sealing of surface 34, which can decrease thebio-reactivity of surface 34 in contact with living tissue. In the caseof some polymer materials which may be used for medium 12, thedensification or carbonization can limit the release of volatile organiccompounds by the medium 12 into surrounding living tissue. Thus, theprocess of the present invention enhances the choices of materials whichmay be used to construct medium 12 and can reduce risk factorsassociated with those material choices.

Studies have suggested that a wide variety of drugs may be useful at thesite of contact between the medical device and the in situ environment.For example, drugs such as anti-coagulants, anti-prolifics, antibiotics,immune-suppressing agents, vasodilators, anti-thrombotic substances,anti-platelet substances, and cholesterol reducing agents may reduceinstances of restenosis when diffused into the blood vessel wall afterinsertion of the stent. Although the present invention is described inreference to stents, its applications and the claims hereof are notlimited to stents and may include any contact with a living body wheredrug delivery may be helpful.

Although the invention has been described with respect to variousembodiments, it should be realized this invention is also capable of awide variety of further and other embodiments within the spirit andscope of the appended claims.

1. A drug delivery system, comprising: a member including a combinationof a drug substance and a polymer or other material; and anencapsulating layer formed in an outer surface of the member by gascluster ion beam irradiation of the outer surface of the member, whichencapsulating layer is adapted to determine a release rate for the drugfrom the member.
 2. The system of claim 1, wherein the encapsulatinglayer includes a plurality of openings located at an outer surface ofthe encapsulating layer and adapted to permit amounts of the drugsubstance to be released from the member at a rate determined by theencapsulating layer.
 3. The system of claim 2, wherein the encapsulatinglayer includes a carbonized or densified matrix.
 4. The system of claim3, wherein the encapsulating layer is adapted to improve a measure ofbiocompatibility of the member.
 5. The system of claim 1, wherein themember is located on a surface of a medical device.
 6. The system ofclaim 1, wherein the drug substance is selected from the groupconsisting of anti-coagulants, antibiotics, anti-tumor substances,immune-suppressing agents, vasodilators, anti-prolifics, anti-thromboticsubstances, anti-platelet substances, cholesterol reducing agents andcombinations thereof.
 7. A medical device including the drug deliverysystem of claim 1.